|
Post by longliner on Apr 8, 2020 11:38:06 GMT -5
Check out MBRX today..interesting news I hope it works, what would the involvement with Mannkind be?
|
|
|
Post by goyocafe on Apr 8, 2020 11:43:02 GMT -5
Check out MBRX today..interesting news How's it going to be delivered?
|
|
|
Post by peppy on Apr 8, 2020 11:53:12 GMT -5
Check out MBRX today..interesting news How's it going to be delivered? MNKD's new motto.
|
|
|
Post by goyocafe on Apr 8, 2020 11:55:37 GMT -5
How's it going to be delivered? MNKD's new motto. As they ride towards the Alamo!
|
|
|
Post by itellthefuture777 on Apr 8, 2020 13:15:59 GMT -5
Immix and MNKD I imagine would ask them how it's going to be delivered..needles are a bad method..
|
|
|
Post by goyocafe on Apr 8, 2020 13:26:59 GMT -5
Immix and MNKD I imagine would ask them how it's going to be delivered..needles are a bad method.. The question is whether Immix and MNKD have their ears to the ground listening for any signs. Just today we've heard about the University of Texas at Austin, though they seem to be aligned with TFF Pharmaceuticals for their delivery already, and MBRX. I like the confidence the director at TFFP has shown in his own company. Bought $100,000 of his stock and the share price jumps. Hint, hint, MC. I also like the homepage for MBRX ("A Message To Our Shareholders"). Hint, hint, MC.
|
|
|
Post by mnholdem on Apr 8, 2020 14:59:51 GMT -5
clinicaltrials.gov/ct2/show/NCT03382340?term=Immix&draw=2&rank=1IMX-110 in Patients With Advanced Solid TumorsStudy Description Brief Summary: Phase 1 is an open-label, multi-center dose escalation/dose expansion study designed to assess the safety, tolerability and pharmacokinetics (PK) for the recommended phase 2 dose (RP2D) of IMX-110. The RP2D will be evaluated in a further dose expansion Phase 2a study submitted.
|
|
|
Post by goyocafe on Apr 8, 2020 17:02:56 GMT -5
clinicaltrials.gov/ct2/show/NCT03382340?term=Immix&draw=2&rank=1IMX-110 in Patients With Advanced Solid TumorsStudy Description Brief Summary: Phase 1 is an open-label, multi-center dose escalation/dose expansion study designed to assess the safety, tolerability and pharmacokinetics (PK) for the recommended phase 2 dose (RP2D) of IMX-110. The RP2D will be evaluated in a further dose expansion Phase 2a study submitted. I'm guessing this was in the pipeline before the collaboration was announced. It doesn't seem like a compound or indication that would be used to treat RDS.
|
|
|
Post by mnholdem on Apr 8, 2020 20:22:04 GMT -5
Correct. The Immix-MannKind collaboration has nothing in human trials. Pre-clinical work must come first before scheduling with the FDA... unless, that is, they are planning an API-device combo where both the drug and device (Dreamboat) are both already approved by the FDA. That would significantly shorten the timeline to Phase 2/3 trial. There is still the issue of who pays for the trial.
|
|
|
Post by barnstormer on Apr 8, 2020 23:47:02 GMT -5
Once again MNKD is working with an unknown company with unknown funds to research a potential CV 19 drug? IMMIX is even more speculative than RLS. I am trying to find some relivance and rationalization for this partnership. When one of your main studies deals with dogs? I love dogs, but Mike needs to help us understand WTF is going on. 1 dog, 2 humans? How did the humans fare? Were they able to go back to their normal routines? Who's financing this Mike? My point is IMMIX has no experience in Corona Virus. Where is the value in this relationship? Are we that desperate to throw this on the wall and see if it sticks? Immix Observes Complete Response in Late-Stage Canine Cancer Patient and Doses First Two Patients in Human Phase 1b/2a Study by Ryan | Aug 6, 2018 | Press Releases | immixbio.com/2018/08/06/immix-observes-complete-response-in-late-stage-canine-cancer-patient-and-doses-first-two-patients-in-human-phase-1b2a-study/LOS ANGELES, Calif. (Aug. 6, 2018, 7:30 AM EST) – Immix Biopharma Inc. announced today that it has observed the complete response of an advanced, spontaneous malignancy in a 10-year-old companion dog after the administration of a single cycle of Imx-110. The dog showed a complete resolution of all clinical signs of disease several days after dosing, with immediate improvement in appetite and energy levels. The patient experienced no decrease in white blood cells – a reaction typically seen with standard treatment doxorubicin – or any other adverse effects. Less than a week after treatment, he returned to his usual activities, according to his owner. While this observed response was impressive, the company cautions that it is still a sample size of 1 and more studies are needed on larger canine patient cohorts.
|
|
|
Post by awesomo on Apr 9, 2020 0:11:31 GMT -5
Immix is a nothing, just like Tanner. It’s a couple of guys using it as their side gig. Look up the three main people in Immix, if you search for their names, Immix doesn’t even show up for any of them.
|
|
|
Post by itellthefuture777 on Apr 9, 2020 1:29:06 GMT -5
Immix is a nothing, just like Tanner. It’s a couple of guys using it as their side gig. Look up the three main people in Immix, if you search for their names, Immix doesn’t even show up for any of them. Vladimir Torchilin, PhD
Co-Founder
Dr. Torchilin is a Distinguished University Professor at Northeastern University, where he directs the Center for Pharmaceutical Biotechnology and Nanomedicine and has served as Chair of the Department of Pharmaceutical Sciences.
Prior to Northeastern, Prof. Torchilin was the Head of Chemistry at Harvard Medical School and Mass General Hospital. He holds more than 45 patents, published more than 400 papers, serves as the Editor-in-Chief of Drug Delivery and Current Drug Discovery Technologies, and was named the world’s 2nd most prolific researcher in pharmacology and toxicology by Times Higher Education.
www.routledge.com/search?pg=1&kw=Vladimir Torchilin&sb=NAN&so=pub&pp=12&view=list&pd=published&publishedFilter=3mo
|
|
|
Post by rfogel on Apr 9, 2020 1:48:25 GMT -5
|
|
|
Post by awesomo on Apr 9, 2020 6:47:18 GMT -5
Immix is a nothing, just like Tanner. It’s a couple of guys using it as their side gig. Look up the three main people in Immix, if you search for their names, Immix doesn’t even show up for any of them. Vladimir Torchilin, PhD
Co-Founder
Dr. Torchilin is a Distinguished University Professor at Northeastern University, where he directs the Center for Pharmaceutical Biotechnology and Nanomedicine and has served as Chair of the Department of Pharmaceutical Sciences.
Prior to Northeastern, Prof. Torchilin was the Head of Chemistry at Harvard Medical School and Mass General Hospital. He holds more than 45 patents, published more than 400 papers, serves as the Editor-in-Chief of Drug Delivery and Current Drug Discovery Technologies, and was named the world’s 2nd most prolific researcher in pharmacology and toxicology by Times Higher Education.
www.routledge.com/search?pg=1&kw=Vladimir Torchilin&sb=NAN&so=pub&pp=12&view=list&pd=published&publishedFilter=3mo
Ok, and? Like I said, Google his name, I went down to page 4 of the results and still didn’t see Immix mentioned once. He’s distinguished, but clearly he is barely associated with Immix and/or Immix is insignificant. www.google.com/search?q=vladimir+torchilin
|
|
|
Post by goyocafe on Apr 9, 2020 6:55:40 GMT -5
Vladimir Torchilin, PhD
Co-Founder
Dr. Torchilin is a Distinguished University Professor at Northeastern University, where he directs the Center for Pharmaceutical Biotechnology and Nanomedicine and has served as Chair of the Department of Pharmaceutical Sciences.
Prior to Northeastern, Prof. Torchilin was the Head of Chemistry at Harvard Medical School and Mass General Hospital. He holds more than 45 patents, published more than 400 papers, serves as the Editor-in-Chief of Drug Delivery and Current Drug Discovery Technologies, and was named the world’s 2nd most prolific researcher in pharmacology and toxicology by Times Higher Education.
www.routledge.com/search?pg=1&kw=Vladimir Torchilin&sb=NAN&so=pub&pp=12&view=list&pd=published&publishedFilter=3mo
Ok, and? Like I said, Google his name, I went down to page 4 of the results and still didn’t see Immix mentioned once. He’s distinguished, but clearly he is barely associated with Immix. www.google.com/search?q=vladimir+torchilinJust playing devil’s advocate for a second, this could be something to do with the Immix website. It may not be getting crawled by search engines for a myriad of reasons, and therefore not associating his name to the company. It seems odd that he’s clearly listed on the website but it doesn’t show up in any searches. immixbio.com/team/Further to this point, search for any name on the Team page and there is no association with Immix in the search results.It seems quite stealthy since you have to work at not being noticed by a search engine. One more example: The following text is straight from the pipeline page on the Immix website “Imx-109 is a small-molecule with preclinical proof-of-concept suggesting its ability to sensitize tumors to checkpoint therapies, cell-based therapies”. And... ”Immix was created to leverage the latest developments in the fields of nanotechnology and drug delivery for the creation of novel and effective cancer therapeutics.” Something this specific would almost always return a hit with this exact text. Not in this case. It’s like they went out of their way to keep their content off the web. Very weird. At least the Immix team isn’t all standing in a forest looking up at the trees.🤣
|
|